




✓
Please replace formula IIIaf on page 28 with the following rewritten formula:

C¹⁷


✓
Please replace formula IVo on page 32 with the following rewritten formula:

C¹⁸

✓
Please replace formula Vi on page 34 with the following rewritten formula:

C¹⁹


✓
Please replace formula Vt on page 36 with the following rewritten formula:

C²⁰

IN THE CLAIMS:

✓
Please amend claims 11, 13, 14, 33, 34, 36, and 38, and enter new claims 41 and 42, as follows:

- Sub
D1/ 11. (Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ia):



C21


in which F^2 is an organic radical which may be joined in a cyclic ring system with G^2 , and which may contain inorganic counterions, but is not a nitrate group; E is a methylene group and G^1 is a methylene group or does not exist; F^1 is H ; and G^2 is $R^N \cdot Z^N \cdot$;

wherein R^N is an organic radical possessing a heteroaryl group containing P or S atoms where said P or S are positioned β , γ , or δ to a nitrate group as identified in formula I; and Z^N is $W^N_{mm} \cdot X^N_{nn} \cdot Y^N_{oo}$;

wherein mm , nn , oo are 0 or 1 and W^N , X^N , Y^N are NH , NR^{NN} , CO , O or CH_2 ;

wherein R^{NN} is a short chain alkyl group ($C_1 - C_{12}$).

- Sub
D2/ 13. (Twice Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ic):



C22

in which E is $(R^1 R^2 C)_m$ and $G^2 - G^1 - CF^1 F^2 -$ is $R^{19} - (R^3 R^4 C)_p - (R^{17} R^{18} C)_n -$;

wherein: m , n , p are integers from 0 to 10;

$R^{3,17}$ are each independently hydrogen, a nitrate group, or A; and

$R^{1,4}$ are each independently hydrogen, or A;

Sub
P₂
cont

where A is selected from a substituted or unsubstituted aliphatic group (comprising a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain, which optionally may contain O, S, NR⁶ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally may contain O, S, NR⁶ and unsaturations in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety constituting a linkage of from 0 to 5 carbons, between R¹ and R³ and/or between R¹⁷ and R⁴, which optionally may contain O, S, NR⁶ and unsaturations in the linkage, and optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups); a substituted or unsubstituted aliphatic group (comprising a branched, cyclic or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain) containing carbonyl linkages (C=O, C=S, C=NOH), which optionally may contain O, S, NR⁶ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, diamino and triamino moieties, arylamino, diarylamino, and alkylarylamino; hydroxy; alkoxy; a substituted or unsubstituted aryloxy;

C22
cont.

wherein X is F, Br, Cl, NO₂, CH₃, CF₂, O, NH, NMe, CN, NHOH, N₂H₃, N₂H₂R¹³, N₂HR¹³R¹⁴, N₃, S, SCN, SCN₂H₂(R¹⁵)₂, SCN₂H₃(R¹⁵), SC(O)N(R¹⁵)₂, SC(O)NHR¹⁵, SO₃M, SH, SR⁷, SO₂M, S(O)R⁸, S(O)₂R⁹, S(O)OR⁸, S(O)₂OR⁹, PO₂HM, PO₃HM, PO₃M₂, P(O)(OR¹⁵)(OR¹⁶), P(O)(OR¹⁶)(OM), P(O)(R¹⁵)(OR⁸), P(O)(OM)R¹⁵, CO₂M, CO₂H, CO₂R¹¹, C(O), C(O)R¹², C(O)(OR¹³), PO₂H, PO₂M, P(O)(OR¹⁴), P(O)(R¹³), SO, SO₂, C(O)(SR¹³), SR⁵, SSR⁷ or SSR⁵;

Y is F, Br, Cl, CH₃, CF₂H, CF₃, OH, NH₂, NHR⁶, NR⁶R⁷, CN, NHOH, N₂H₃, N₂H₂R¹³, N₂HR¹³R¹⁴, N₃, S, SCN, SCN₂H₂(R¹⁵)₂, SCN₂H₃(R¹⁵), SC(O)N(R¹⁵)₂, SC(O)NHR¹⁵, SO₃M, SH, SR⁷, SO₂M, S(O)R⁸, S(O)₂R⁹, S(O)OR⁸, S(O)₂OR⁹, PO₂HM, PO₃M₂, P(O)(OR¹⁵)(OR¹⁶), P(O)(OR¹⁶)(OM), P(O)(R¹⁵)(OR⁸), P(O)(OM)R¹⁵, CO₂M, CO₂H, CO₂R¹¹, C(O)R¹², C(O)(OR¹³), C(O)(SR¹³), SR⁵, SSR⁷ or SSR⁵, or does not exist;

R², R⁵, R¹⁸, R¹⁹ are optionally hydrogen, A or X-Y;

R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ are the same or different alkyl or acyl groups containing 1-24 carbon atoms which may contain 1-4 ONO₂ substituents; or C₁ - C₆ connections to R¹ - R⁴ in cyclic derivatives which may contain 1-4 ONO₂ substituents; or are each independently hydrogen, a nitrate group or A;

C 22
cont.

M is H, Na⁺, K⁺, NH₄⁺, N⁺H_kR¹¹ (4-13) where k is 0-3; or other pharmaceutically acceptable counterion;

and with the proviso that when m = n = p = 1 and R¹⁹, R², R¹⁸, R¹ = H and R¹⁷, R³ are nitrate groups, R⁴ is not H.

C 23
cont.

14. (Amended) The method of claim 11, wherein F² is a nitrate group; and E, F¹, G¹, G² are the same or different organic radicals which may be joined in cyclic ring systems, and which may contain inorganic counterions;

with the proviso that when E and G¹ are methylene groups and F¹ is H, G² is not a nitrate group, nor R^NZ^N;

wherein R^N is any aryl or heteroaryl group and Z^N is (CO)_{mm}X^N_{nn}Y^N_{oo};


wherein mm, nn, oo are 0 or 1 and X^N, Y^N are NH, NR^{NN}, O or CH₂;

wherein R^{NN} is a short chain alkyl group (C₁ - C₁₂).


33. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:

C 24


IIIa




IIIb




IIIc




IIIId




IIIe




III f




IIIg




IIIh




IIIi




IIIj




IIIk




IIIl






C 24
cont.

IIIIm















IIIIn






124
cont.


III_tIII_uIII_vIII_wIII_xIII_y24
cont.




IIIaf




IIIag




IIIah




IIIai




IIIaj




IIIak


C24
cont.





, and









34. (Amended) The method of claim 33, wherein the compound has the formula IIIc:









36. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:











C 25
Cont.




25
cont.




38. (Amended) A method of mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:




Vb




Vc




Vd




Ve




Vf




Vg




Vh




Vi




Vj




Vk




Vl




Vm




Vn

26
cont.


Vo




Vp




Vq




Vr



Vs




Vt




26
cont.


Vu




Vv




Vw




Vx




Vy




Vz

126
cont.


Vaa




Vab




Vac




Vad




Vae



Vaf



Vag



, and